Literature DB >> 10499621

Telomerase assay for differentiating between malignancy-related and nonmalignant ascites.

P Tangkijvanich1, D Tresukosol, P Sampatanukul, S Sakdikul, N Voravud, V Mahachai, A Mutirangura.   

Abstract

The differential diagnosis between malignancy-related ascites (MRAs) and nonmalignant ascites (NMAs) has remained an essential problem in clinical practice. Our purpose was to determine the diagnostic value of ascitic fluid telomerase activity in discriminating these two categories compared with that of cytological examination. Twenty-five MRAs and 47 NMAs as the control group were enrolled in our study. In the MRA group, telomerase activity was detected in 13 of 16 (81.3%) cases of peritoneal carcinomatosis and in 6 of 9 (66.7%) cases of hepatocellular carcinoma (HCC)-associated ascites. Contrasting that, cytological examination was positive in only 9 of 16 (56.3%) and 1 of 9 (11.1%) cases, respectively. In the NMA group, telomerase-positive ascitic fluid samples were found in 2 of 47 (4.3%) cases, all belonging to subgroups that contained large numbers of lymphocytes in the ascites. In our study, the telomerase activity and cytological examination exhibited a sensitivity of 76% and 40% and a specificity of 95.7% and 100%, respectively. Regarding subgroups of MRAs, the telomerase activity and cytological examination demonstrated a sensitivity of 81.3% and 56.3%, respectively, in peritoneal carcinomatosis and a sensitivity of 66.7% and 11.1%, respectively, in HCC-associated ascites. In conclusion, telomerase activity is a more sensitive marker than cytological examination for differentiating between MRAs and NMAs. It may also serve as a useful indicator for detecting early i.p. metastasis in HCC-associated ascites.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499621

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures.

Authors:  Suma L Sangisetty; Thomas J Miner
Journal:  World J Gastrointest Surg       Date:  2012-04-27

2.  A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites.

Authors:  Ahmed Abdel-Razik; Nasser Mousa; Hatem Elalfy; Tarek Fouad Sheta; Mahmoud Awad; Mostafa Abdelsalam; Rania Elhelaly; Rasha Elzehery; Nawal S Gouda; Waleed Eldars
Journal:  J Gastrointest Cancer       Date:  2017-03

3.  Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignancies.

Authors:  Chung-Pin Li; Tze-Sing Huang; Yee Chao; Full-Young Chang; Jacquline Whang-Peng; Shou-Dong Lee
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

4.  Telomerase detection in the diagnosis and prognosis of cancer.

Authors:  Eiso Hiyama; Keiko Hiyama
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

5.  Change of telomerase activity in peripheral blood of patients with head and neck squamous cell carcinoma pre and post curative treatment.

Authors:  M S Ganesh; Geeta S Narayanan; Rishabh Kumar
Journal:  Rep Pract Oncol Radiother       Date:  2019-12-01

6.  Telomerase activity assay for the diagnosis of malignant pleural effusion: A meta-analysis.

Authors:  Yong-Chun Shen; Zhen-Ni Chen; Ting Yang; Lei Chen; Tao Wang; Fu-Qiang Wen; Qun Yi
Journal:  Exp Ther Med       Date:  2012-06-26       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.